Zhou Chong, Yool Andrea J, Nolan James, Byard Roger W
Medical School, The University of Adelaide, Frome Road, Adelaide, SA, 5005, Australia.
J Forensic Sci. 2013 Jan;58 Suppl 1:S94-8. doi: 10.1111/j.1556-4029.2012.02274.x. Epub 2012 Sep 12.
Armanni-Ebstein lesions were first described by Luciano Armanni, a pathologist at the University of Naples, during autopsy studies undertaken in 1872, as a unique vacuolar nephropathy associated with poorly controlled diabetes that involves selective renal epithelial cell glycogen accumulation. However, within the last two decades, a broader range of vacuolar changes, including lipid deposition, have also been termed Armanni-Ebstein (AE) lesions, creating some confusion on possible etiology. We would suggest that the term AE phenomenon would be best reserved for the original clear cell change associated with glycogen deposition, and that this should be clearly distinguished from subnuclear lipid vacuolization ("basal vacuolization"). Although there is obvious inter-relation between these two types of vacuoles, they appear morphologically and biochemically distinct from each other. More precise classification may assist in clarifying the causal processes and possible diagnostic significance of different types of renal epithelial vacuolization at autopsy.
阿尔曼尼-埃布斯坦病变最早由那不勒斯大学的病理学家卢西亚诺·阿尔曼尼在1872年进行尸检研究时描述，是一种与糖尿病控制不佳相关的独特空泡性肾病，涉及选择性肾上皮细胞糖原积累。然而，在过去二十年中，包括脂质沉积在内的更广泛的空泡变化也被称为阿尔曼尼-埃布斯坦（AE）病变，这在可能的病因方面造成了一些混淆。我们建议，AE现象这一术语最好保留用于与糖原沉积相关的原始透明细胞变化，并且应将其与核下脂质空泡化（“基底空泡化”）明确区分开来。尽管这两种类型的空泡之间存在明显的相互关系，但它们在形态和生化上似乎彼此不同。更精确的分类可能有助于阐明尸检时不同类型肾上皮空泡化的因果过程和可能的诊断意义。
